- Home
- PRTG vs ATHA Comparison
PRTG vs ATHA Comparison
Compare PRTG & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTG
- ATHA
- Stock Information
- Founded
- PRTG 1973
- ATHA 2011
- Country
- PRTG British Virgin Islands
- ATHA United States
- Employees
- PRTG N/A
- ATHA N/A
- Industry
- PRTG Oil & Gas Production
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- PRTG Energy
- ATHA Health Care
- Exchange
- PRTG Nasdaq
- ATHA Nasdaq
- Market Cap
- PRTG 17.7M
- ATHA 14.8M
- IPO Year
- PRTG N/A
- ATHA 2020
- Fundamental
- Price
- PRTG $8.85
- ATHA $0.38
- Analyst Decision
- PRTG
- ATHA Buy
- Analyst Count
- PRTG 0
- ATHA 4
- Target Price
- PRTG N/A
- ATHA $11.25
- AVG Volume (30 Days)
- PRTG 44.3K
- ATHA 191.8K
- Earning Date
- PRTG 08-26-2025
- ATHA 08-07-2025
- Dividend Yield
- PRTG N/A
- ATHA N/A
- EPS Growth
- PRTG N/A
- ATHA N/A
- EPS
- PRTG N/A
- ATHA N/A
- Revenue
- PRTG N/A
- ATHA N/A
- Revenue This Year
- PRTG N/A
- ATHA N/A
- Revenue Next Year
- PRTG N/A
- ATHA N/A
- P/E Ratio
- PRTG N/A
- ATHA N/A
- Revenue Growth
- PRTG N/A
- ATHA N/A
- 52 Week Low
- PRTG $2.10
- ATHA $0.22
- 52 Week High
- PRTG $23.01
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- PRTG 65.34
- ATHA 49.40
- Support Level
- PRTG $8.08
- ATHA $0.36
- Resistance Level
- PRTG $10.25
- ATHA $0.40
- Average True Range (ATR)
- PRTG 0.87
- ATHA 0.04
- MACD
- PRTG 0.43
- ATHA -0.01
- Stochastic Oscillator
- PRTG 71.72
- ATHA 30.60
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.